Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai, India.
Johns Hopkins University School of Medicine, Baltimore, USA.
HIV Med. 2024 Jul;25(7):852-861. doi: 10.1111/hiv.13641. Epub 2024 Apr 25.
To study the prevalence of low-level viraemia (LLV) and its association with virological failure (VF).
We conducted a retrospective analysis of 3498 participants at YRG CARE, Chennai, India (2013-2018) on antiretroviral therapy (ART) for ≥6 months with two or more plasma viral load (pVL) measurements. Results were stratified for those with pVL <1000 copies/mL: fully suppressed (FS) (pVL <40), low-LLV (pVL 40-199), mid-LLV (pVL 200-399), and high-LLV (pVL 400-999). The study assessed the association with VF (pVL >1000 copies/mL) using Cox proportional hazard model.
Among 3498 participants, 2965 (84.8%) were FS and 533 (15.2%) were LLV. During the follow-up, 348 (10%) experienced VF, with 222 (6.3%) experienced after LLV (42% of LLV) and 126 (3.6%) experienced after FS (4.3% of FS). When compared with FS, those with LLV had a greater risk of VF [adjusted hazard ratio (aHR) = 12.7; 95% confidence interval (CI): 10.2-15.9]. First-line participants had a higher VF incidence (aHR = 15.8, 95% CI: 11.4-21.9) than second-line participants (aHR = 5.6, 95% CI: 4.1-7.7). Those with high-LLV had the highest VF risk (aHR = 22.856, 95% CI: 15.204-34.359 vs. aHR = 8.186, 95% CI: 5.564-12.043, for first-line vs. second-line participants, respectively), followed by those with mid-LLV (aHR = 13.375, 95% CI: 8.327-21.483 vs. aHR = 6.261, 95% CI: 4.044-9.695) and low-LLV (aHR = 12.976, 95% CI: 7.974-21.118 vs. aHR = 4.158, 95% CI: 2.826-6.119).
The prevalence of LLV was intermediate in our study population. There was a higher risk of VF among individuals with LLV, and this risk increased with the increasing levels of LLV. Close monitoring of individuals experiencing LLV could help in the early identification of VF.
研究低水平病毒血症(LLV)的流行情况及其与病毒学失败(VF)的关系。
我们对印度钦奈 YRG CARE 的 3498 名接受了至少 6 个月抗逆转录病毒治疗(ART)且有两次或以上血浆病毒载量(pVL)测量值的患者进行了回顾性分析。结果按 pVL<1000 拷贝/ml 进行分层:完全抑制(FS)(pVL<40)、低 LLV(pVL40-199)、中 LLV(pVL200-399)和高 LLV(pVL400-999)。该研究使用 Cox 比例风险模型评估与 VF(pVL>1000 拷贝/ml)的相关性。
在 3498 名参与者中,2965 名(84.8%)为 FS,533 名(15.2%)为 LLV。在随访期间,348 名(10%)发生了 VF,其中 222 名(6.3%)在发生 LLV 后(LLV 的 42%),126 名(3.6%)在发生 FS 后(FS 的 4.3%)。与 FS 相比,LLV 患者发生 VF 的风险更高[调整后的危险比(aHR)=12.7;95%置信区间(CI):10.2-15.9]。一线治疗患者的 VF 发生率(aHR=15.8,95%CI:11.4-21.9)高于二线治疗患者(aHR=5.6,95%CI:4.1-7.7)。高 LLV 患者的 VF 风险最高(aHR=22.856,95%CI:15.204-34.359 比 aHR=8.186,95%CI:5.564-12.043,一线治疗比二线治疗,分别),其次是中 LLV 患者(aHR=13.375,95%CI:8.327-21.483 比 aHR=6.261,95%CI:4.044-9.695)和低 LLV 患者(aHR=12.976,95%CI:7.974-21.118 比 aHR=4.158,95%CI:2.826-6.119)。
在我们的研究人群中,LLV 的流行率处于中等水平。LLV 患者发生 VF 的风险较高,且随着 LLV 水平的升高而增加。对出现 LLV 的患者进行密切监测有助于早期发现 VF。